Synthaverse S.A. (SVE.WA)

PLN 4.28

(7.0%)

EBITDA Summary of Synthaverse S.A.

  • Synthaverse S.A.'s latest annual EBITDA in 2023 was 15.34 Million PLN , down -1.55% from previous year.
  • Synthaverse S.A.'s latest quarterly EBITDA in 2024 Q2 was 4.31 Million PLN , up 62.72% from previous quarter.
  • Synthaverse S.A. reported an annual EBITDA of 15.4 Million PLN in 2022, up 10.16% from previous year.
  • Synthaverse S.A. reported an annual EBITDA of 13.09 Million PLN in 2021, up 117.64% from previous year.
  • Synthaverse S.A. reported a quarterly EBITDA of 4.31 Million PLN for 2024 Q2, up 62.72% from previous quarter.
  • Synthaverse S.A. reported a quarterly EBITDA of 6.96 Million PLN for 2023 Q4, up 704.77% from previous quarter.

Annual EBITDA Chart of Synthaverse S.A. (2023 - 2010)

Historical Annual EBITDA of Synthaverse S.A. (2023 - 2010)

Year EBITDA EBITDA Growth
2023 15.34 Million PLN -1.55%
2022 15.4 Million PLN 10.16%
2021 13.09 Million PLN 117.64%
2020 10.84 Million PLN -44.22%
2019 11.65 Million PLN 7669.33%
2018 -29.48 Million PLN 107.38%
2017 11.9 Million PLN -21.45%
2016 -17.87 Million PLN 94.52%
2015 -30.52 Million PLN -725.54%
2014 4.47 Million PLN -34.05%
2013 5.45 Million PLN 14026.54%
2012 -1.48 Million PLN -100.77%
2011 6.83 Million PLN 548.42%
2010 7.57 Million PLN 0.0%

Peer EBITDA Comparison of Synthaverse S.A.

Name EBITDA EBITDA Difference
Bioceltix S.A. -13.22 Million PLN 216.043%
BIOTON S.A. 43.89 Million PLN 65.041%
Captor Therapeutics Spolka Akcyjna -64.76 Million PLN 123.695%
Mabion S.A. 58.31 Million PLN 73.683%
Molecure S.A. -25.5 Million PLN 160.167%
NanoGroup S.A. -7.87 Million PLN 294.987%
Pharmena S.A. 33.78 Million PLN 54.571%
Poltreg S.A. -11.65 Million PLN 231.624%
Pure Biologics Spólka Akcyjna -26.07 Million PLN 158.849%
Ryvu Therapeutics S.A. -81.04 Million PLN 118.935%
Urteste S.A. -5.73 Million PLN 367.772%